View in EDS PDF Full Text

Suspensión de medicamentos anticrisis.

Saved in:
Bibliographic Details
Title: Suspensión de medicamentos anticrisis.
Alternate Title: Discontinuation of anti-seizure medications.
Authors: Mena-Barranco, Francisco J.1 fmenabarranco@yahoo.com.mx, Carrillo-Mora, Paul2, del Rocío Márquez-Estudillo, M.3, Molina-García, Avril4, Pelayo-González, Mónica E.5, Silva-Sánchez, Sandra E.6, Villegas-Peña, Hilda7
Source: Revista Mexicana de Neurociencia. 2026 Supplement, Vol. 27, p158-165. 8p.
Abstract (English): The decision to continue or discontinue anti-seizure medications (ASMs) is highly relevant and should be made jointly by the patient, family and/or caregivers, and the specialist physician, after comprehensive information is provided. The patient and family must recognize that there will always be a risk of seizure recurrence with or without ASMs, and the type of epilepsy, its prognosis, and the patient's lifestyle must be considered. Discontinuation will be under the supervision of a specialist (clinical neurologist) and will be considered after at least two years without seizures, in addition to other requirements. Treatment will be withdrawn gradually over a period of at least 2-3 months, with ASMs being discontinued one at a time. The withdrawal of benzodiazepines and barbiturates will be slower, taking no less than 6 months. An agreement must be reached that in the event of a seizure relapse, the last dose prior to the dose at which the relapse occurred will be reinstated, and a specialist evaluation will be requested. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Es una decisión de alta relevancia, cuando llega el momento, continuar o retirar los medicamentos anticrisis (MAC), y debe ser tomada en conjunto por el paciente, la familia y/o los cuidadores y el médico especialista, después de una amplia información al respecto. El paciente y los familiares deben reconocer que siempre habrá un riesgo de recurrencia de crisis con y sin MAC, y se debe tomar en cuenta el tipo de epilepsia, el pronóstico de esta y el estilo de vida del paciente. El retiro será bajo la supervisión de un especialista (neurólogo clínico) y se considerará cuando se hayan cumplido por los menos dos años sin crisis, además de otros requisitos. El tratamiento será retirado de manera gradual, en un lapso de al menos 2-3 meses, y se retirarán los MAC uno por uno. El retiro de benzodiazepinas y barbitúricos será más lento, en no menos de 6 meses. Se deberá tener un acuerdo de que en caso de recaída de crisis se regresará a la última dosis previa a la dosis en la cual se presentó la recaída y se solicitará valoración por el especialista. [ABSTRACT FROM AUTHOR]
Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 195358924
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Suspensión de medicamentos anticrisis.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Discontinuation of anti-seizure medications.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Mena-Barranco%2C+Francisco+J%2E%22">Mena-Barranco, Francisco J.</searchLink><relatesTo>1</relatesTo><i> fmenabarranco@yahoo.com.mx</i><br /><searchLink fieldCode="AR" term="%22Carrillo-Mora%2C+Paul%22">Carrillo-Mora, Paul</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22del+Rocío+Márquez-Estudillo%2C+M%2E%22">del Rocío Márquez-Estudillo, M.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Molina-García%2C+Avril%22">Molina-García, Avril</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Pelayo-González%2C+Mónica+E%2E%22">Pelayo-González, Mónica E.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Silva-Sánchez%2C+Sandra+E%2E%22">Silva-Sánchez, Sandra E.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Villegas-Peña%2C+Hilda%22">Villegas-Peña, Hilda</searchLink><relatesTo>7</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Mexicana+de+Neurociencia%22">Revista Mexicana de Neurociencia</searchLink>. 2026 Supplement, Vol. 27, p158-165. 8p.
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: The decision to continue or discontinue anti-seizure medications (ASMs) is highly relevant and should be made jointly by the patient, family and/or caregivers, and the specialist physician, after comprehensive information is provided. The patient and family must recognize that there will always be a risk of seizure recurrence with or without ASMs, and the type of epilepsy, its prognosis, and the patient's lifestyle must be considered. Discontinuation will be under the supervision of a specialist (clinical neurologist) and will be considered after at least two years without seizures, in addition to other requirements. Treatment will be withdrawn gradually over a period of at least 2-3 months, with ASMs being discontinued one at a time. The withdrawal of benzodiazepines and barbiturates will be slower, taking no less than 6 months. An agreement must be reached that in the event of a seizure relapse, the last dose prior to the dose at which the relapse occurred will be reinstated, and a specialist evaluation will be requested. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Es una decisión de alta relevancia, cuando llega el momento, continuar o retirar los medicamentos anticrisis (MAC), y debe ser tomada en conjunto por el paciente, la familia y/o los cuidadores y el médico especialista, después de una amplia información al respecto. El paciente y los familiares deben reconocer que siempre habrá un riesgo de recurrencia de crisis con y sin MAC, y se debe tomar en cuenta el tipo de epilepsia, el pronóstico de esta y el estilo de vida del paciente. El retiro será bajo la supervisión de un especialista (neurólogo clínico) y se considerará cuando se hayan cumplido por los menos dos años sin crisis, además de otros requisitos. El tratamiento será retirado de manera gradual, en un lapso de al menos 2-3 meses, y se retirarán los MAC uno por uno. El retiro de benzodiazepinas y barbitúricos será más lento, en no menos de 6 meses. Se deberá tener un acuerdo de que en caso de recaída de crisis se regresará a la última dosis previa a la dosis en la cual se presentó la recaída y se solicitará valoración por el especialista. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=195358924
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 158
    Titles:
      – TitleFull: Suspensión de medicamentos anticrisis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mena-Barranco, Francisco J.
      – PersonEntity:
          Name:
            NameFull: Carrillo-Mora, Paul
      – PersonEntity:
          Name:
            NameFull: del Rocío Márquez-Estudillo, M.
      – PersonEntity:
          Name:
            NameFull: Molina-García, Avril
      – PersonEntity:
          Name:
            NameFull: Pelayo-González, Mónica E.
      – PersonEntity:
          Name:
            NameFull: Silva-Sánchez, Sandra E.
      – PersonEntity:
          Name:
            NameFull: Villegas-Peña, Hilda
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 05
              Text: 2026 Supplement
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 16655044
          Numbering:
            – Type: volume
              Value: 27
          Titles:
            – TitleFull: Revista Mexicana de Neurociencia
              Type: main
ResultId 1